Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

CORT

+ Watchlist+ Portfolio

Corcept Therapeutics Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$70.07
52-Week Range
$28.66 – $126.38
Market Cap
$7.42B
P/E (TTM)
50.97
EPS (TTM)
1.33
Dividend Yield
0.00%
Advanced Metrics
Price/Book
8.89
PEG Ratio
0.81
Return on Equity
22.15%
Return on Assets
7.46%
Gross Margin
98.54%
Operating Margin
11.51%
Profit Margin
16.84%
Current Ratio
3.00
Debt/Equity
0.01
Total Debt
$8.99M
Free Cash Flow
$132.18M
Revenue Growth
64.00%
Earnings Growth
531.30%
Enterprise Value
$7.06B

Market Snapshot

About

Corcept Therapeutics Inc. is a pharmaceutical company focused on the discovery and development of medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effects of cortisol. Headquartered in Menlo Park, California, the company's lead product is Korlym (mifepristone), approved for treating Cushing's syndrome, a rare disease caused by excess cortisol. Corcept has a pipeline of selective cortisol modulators in development for various conditions including ovarian cancer, prostate cancer, and antipsychotic-induced weight gain. The company holds extensive intellectual property around cortisol modulation therapies.